Abstract #2481

Tumor necrosis factor (TNF) antagonist therapy in small bowel Crohn’s disease (CD): association of the apparent diffusion coefficient (ADC) with treatment response.

Bradley Spieler¹, Hector De Jesus¹, Christopher Rouse¹, Catherine Hudson², Scott Kleinpeter³, Catherine Batte⁴, Raman Danrad¹, and Kara De Felice⁵

¹Radiology, LSUHSC New Orleans, New Orleans, LA, United States, ²Internal Medicine, LSUHSC New Orleans, New Orleans, LA, United States, ³School of Medicine, LSUHSC New Orleans, New Orleans, LA, United States, ⁴LSU, Baton Rouge, LA, United States, ⁵Gastroenterology, LSUHSC New Orleans, New Orleans, LA, United States

Diffusion weighted imaging (DWI) has proven beneficial in the assessment of disease activity and therapeutic response in a myriad of pathology. Studies have shown an inversely proportional correlation between bowel inflammation in Crohn’s disease (CD) and apparent diffusion coefficient (ADC) values of involved bowel wall. This beckons an intriguing opportunity for gauging treatment response, particularly with respect to some of the most commonly used agents, tumor necrosis factor (TNF) antagonists. This study retrospectively measured the ADC value of affected small bowel segments before and after anti-TNF infusion therapy and compares it to the clinical response in patients with active CD.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.